WallStSmart

Kenvue Inc. (KVUE)vsNu Skin Enterprises Inc (NUS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Kenvue Inc. generates 961% more annual revenue ($15.29B vs $1.44B). KVUE leads profitability with a 10.6% profit margin vs 3.8%. NUS appears more attractively valued with a PEG of 0.78. KVUE earns a higher WallStSmart Score of 66/100 (B-).

KVUE

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 5.3Quality: 4.5
Piotroski: 3/9Altman Z: 1.22

NUS

Buy

52

out of 100

Grade: C-

Growth: 2.0Profit: 4.5Value: 9.3Quality: 8.0
Piotroski: 5/9Altman Z: 4.17
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

KVUEOvervalued (-14.9%)

Margin of Safety

-14.9%

Fair Value

$16.14

Current Price

$17.59

$1.45 premium

UndervaluedFair: $16.14Overvalued
NUSUndervalued (+66.3%)

Margin of Safety

+66.3%

Fair Value

$30.15

Current Price

$7.16

$22.99 discount

UndervaluedFair: $30.15Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KVUE2 strengths · Avg: 8.0/10
Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

EPS GrowthGrowth
46.9%8/10

Earnings expanding 46.9% YoY

NUS4 strengths · Avg: 9.5/10
P/E RatioValuation
6.6x10/10

Attractively priced relative to earnings

Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
4.1710/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.788/10

Growing faster than its price suggests

Areas to Watch

KVUE3 concerns · Avg: 3.0/10
Revenue GrowthGrowth
4.5%4/10

4.5% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

NUS4 concerns · Avg: 3.0/10
Market CapQuality
$352.11M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Profit MarginProfitability
3.8%3/10

3.8% margin — thin

Operating MarginProfitability
1.8%3/10

Operating margin of 1.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : KVUE

The strongest argument for KVUE centers on Operating Margin, EPS Growth.

Bull Case : NUS

The strongest argument for NUS centers on P/E Ratio, Price/Book, Altman Z-Score. PEG of 0.78 suggests the stock is reasonably priced for its growth.

Bear Case : KVUE

The primary concerns for KVUE are Revenue Growth, Piotroski F-Score, Altman Z-Score.

Bear Case : NUS

The primary concerns for NUS are Market Cap, Return on Equity, Profit Margin. Thin 3.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

NUS carries more volatility with a beta of 1.02 — expect wider price swings.

KVUE is growing revenue faster at 4.5% — sustainability is the question.

KVUE generates stronger free cash flow (350M), providing more financial flexibility.

Monitor HOUSEHOLD & PERSONAL PRODUCTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

KVUE scores higher overall (66/100 vs 52/100). NUS offers better value entry with a 66.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Kenvue Inc.

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Kenvue Inc. is a consumer health company globally.

Visit Website →

Nu Skin Enterprises Inc

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Nu Skin Enterprises, Inc. develops and distributes wellness and personal care products globally. The company is headquartered in Provo, Utah.

Visit Website →

Want to dig deeper into these stocks?